| Dr Dustin J Wiles, OD | |
|
1605 Martin Springs Dr Ste 240a, Rolla, MO 65401 | |
| (573) 458-6310 | |
| Not Available |
| Full Name | Dr Dustin J Wiles |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 12 Years |
| Location | 1605 Martin Springs Dr Ste 240a, Rolla, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033473566 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 2012019973 (Missouri) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Clinic Springfield Communities | 7416865845 | 922 |
News Archive
A clinical trial using an all-natural lozenge to treat dry mouth, a condition that impacts 40 percent of American adults, is under way at Georgia Health Sciences University College of Dental Medicine.
Cepheid today announced the international availability of an update to Xpert Carba-R, with the addition of two newly emerging carbapenemase genes, OXA-181 and OXA-232. The on-demand, molecular test also detects and differentiates among the five most prevalent mechanisms of carbapenem resistance, namely KPC, NDM, VIM, IMP-1 and OXA-48.
The Auditor General's report on the Queensland health pay bungle revealed an "unprecedented failure of public administration in Queensland" a day after two senior bureaucrats lost their jobs.
Mundipharma EDO GmbH (Early Development in Oncology) is pleased to announce that the United States Food and Drug Administration has accepted the company's Investigational New Drug Application ("IND") for EDO-S101, a fusion molecule to treat relapsed/refractory haematologic malignancies and solid tumours.
› Verified 5 days ago
| Provider Name | Mercy Clinic Springfield Communities |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1245277631 PECOS PAC ID: 7416865845 Enrollment ID: O20031104000060 |
News Archive
A clinical trial using an all-natural lozenge to treat dry mouth, a condition that impacts 40 percent of American adults, is under way at Georgia Health Sciences University College of Dental Medicine.
Cepheid today announced the international availability of an update to Xpert Carba-R, with the addition of two newly emerging carbapenemase genes, OXA-181 and OXA-232. The on-demand, molecular test also detects and differentiates among the five most prevalent mechanisms of carbapenem resistance, namely KPC, NDM, VIM, IMP-1 and OXA-48.
The Auditor General's report on the Queensland health pay bungle revealed an "unprecedented failure of public administration in Queensland" a day after two senior bureaucrats lost their jobs.
Mundipharma EDO GmbH (Early Development in Oncology) is pleased to announce that the United States Food and Drug Administration has accepted the company's Investigational New Drug Application ("IND") for EDO-S101, a fusion molecule to treat relapsed/refractory haematologic malignancies and solid tumours.
› Verified 5 days ago
| Provider Name | Mercy Clinic Springfield Communities |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1972771657 PECOS PAC ID: 7416865845 Enrollment ID: O20031218000354 |
News Archive
A clinical trial using an all-natural lozenge to treat dry mouth, a condition that impacts 40 percent of American adults, is under way at Georgia Health Sciences University College of Dental Medicine.
Cepheid today announced the international availability of an update to Xpert Carba-R, with the addition of two newly emerging carbapenemase genes, OXA-181 and OXA-232. The on-demand, molecular test also detects and differentiates among the five most prevalent mechanisms of carbapenem resistance, namely KPC, NDM, VIM, IMP-1 and OXA-48.
The Auditor General's report on the Queensland health pay bungle revealed an "unprecedented failure of public administration in Queensland" a day after two senior bureaucrats lost their jobs.
Mundipharma EDO GmbH (Early Development in Oncology) is pleased to announce that the United States Food and Drug Administration has accepted the company's Investigational New Drug Application ("IND") for EDO-S101, a fusion molecule to treat relapsed/refractory haematologic malignancies and solid tumours.
› Verified 5 days ago
| Provider Name | Complete Vision Care Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1497895908 PECOS PAC ID: 4981737095 Enrollment ID: O20100726000851 |
News Archive
A clinical trial using an all-natural lozenge to treat dry mouth, a condition that impacts 40 percent of American adults, is under way at Georgia Health Sciences University College of Dental Medicine.
Cepheid today announced the international availability of an update to Xpert Carba-R, with the addition of two newly emerging carbapenemase genes, OXA-181 and OXA-232. The on-demand, molecular test also detects and differentiates among the five most prevalent mechanisms of carbapenem resistance, namely KPC, NDM, VIM, IMP-1 and OXA-48.
The Auditor General's report on the Queensland health pay bungle revealed an "unprecedented failure of public administration in Queensland" a day after two senior bureaucrats lost their jobs.
Mundipharma EDO GmbH (Early Development in Oncology) is pleased to announce that the United States Food and Drug Administration has accepted the company's Investigational New Drug Application ("IND") for EDO-S101, a fusion molecule to treat relapsed/refractory haematologic malignancies and solid tumours.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Dustin J Wiles, OD 1605 Martin Springs Dr Ste 240a, Rolla, MO 65401-2980 Ph: (573) 458-6310 | Dr Dustin J Wiles, OD 1605 Martin Springs Dr Ste 240a, Rolla, MO 65401 Ph: (573) 458-6310 |
News Archive
A clinical trial using an all-natural lozenge to treat dry mouth, a condition that impacts 40 percent of American adults, is under way at Georgia Health Sciences University College of Dental Medicine.
Cepheid today announced the international availability of an update to Xpert Carba-R, with the addition of two newly emerging carbapenemase genes, OXA-181 and OXA-232. The on-demand, molecular test also detects and differentiates among the five most prevalent mechanisms of carbapenem resistance, namely KPC, NDM, VIM, IMP-1 and OXA-48.
The Auditor General's report on the Queensland health pay bungle revealed an "unprecedented failure of public administration in Queensland" a day after two senior bureaucrats lost their jobs.
Mundipharma EDO GmbH (Early Development in Oncology) is pleased to announce that the United States Food and Drug Administration has accepted the company's Investigational New Drug Application ("IND") for EDO-S101, a fusion molecule to treat relapsed/refractory haematologic malignancies and solid tumours.
› Verified 5 days ago
Dr. Dennis William Garstang, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 500 S Bishop Ave, Rolla, MO 65401 Phone: 573-341-9491 | |
Dr. Vernon Edward Falkenhain, O.D. Optometrist Medicare: May Accept Medicare Assignments Practice Location: 1001 N Pine St, Rolla, MO 65401 Phone: 573-364-1773 Fax: 573-341-3945 | |
Dr. Angela Marie Appleman, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1605 Martin Springs Dr, Ste 240 A, Rolla, MO 65401 Phone: 573-458-6310 | |
Pg Optical Llc Optometrist Medicare: Medicare Enrolled Practice Location: 306 N Bishop Ave Ste B, Rolla, MO 65401 Phone: 573-426-6779 | |
Dr. Matthew James Blanton, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 500 S Bishop Ave, Rolla, MO 65401 Phone: 573-341-9490 Fax: 573-341-9495 | |
Vernon Gary Green, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1211 Hauck Dr, Rolla, MO 65401 Phone: 573-364-6300 Fax: 573-341-5058 |